Affimed (AFMD) News Today $3.10 -0.04 (-1.27%) (As of 10/9/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Analysts Set Affimed (NASDAQ:AFMD) Target Price at $20.00October 6, 2024 | americanbankingnews.comAffimed (NASDAQ:AFMD) Given Average Rating of "Buy" by BrokeragesAffimed (NASDAQ:AFMD - Get Free Report) has earned a consensus rating of "Buy" from the four research firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issuOctober 3, 2024 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Affimed (AFMD)September 24, 2024 | markets.businessinsider.comAffimed N.V. (A28A.F)September 11, 2024 | sg.finance.yahoo.comAffimed to Present at the Cantor Global Healthcare Conference 2024September 10, 2024 | globenewswire.comAffimed (NASDAQ:AFMD) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Affimed in a report on Monday.September 9, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Receives Average Rating of "Buy" from AnalystsShares of Affimed (NASDAQ:AFMD - Get Free Report) have received a consensus recommendation of "Buy" from the four ratings firms that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers thaSeptember 8, 2024 | marketbeat.comAffimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | msn.comBuy Rating Justified by Promising Clinical Data and Solid Progress in Affimed’s Drug DevelopmentsSeptember 6, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Affimed (NASDAQ:AFMD)HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Affimed in a report on Friday.September 6, 2024 | marketbeat.comAffimed Reports Second Quarter 2024 Financial Results & Business UpdateSeptember 5, 2024 | markets.businessinsider.comAffimed N.V. (AFMD) Q2 2024 Earnings Call TranscriptSeptember 5, 2024 | seekingalpha.comAffimed Appoints Shawn M. Leland as Chief Executive OfficerSeptember 3, 2024 | globenewswire.comAffimed (AFMD) Scheduled to Post Earnings on ThursdayAffimed (NASDAQ:AFMD) will be releasing earnings before the market opens on Thursday, September 5, Zacks reports.August 30, 2024 | marketbeat.comAffimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024August 29, 2024 | globenewswire.comAffimed (NASDAQ:AFMD) Stock Price Crosses Below 200 Day Moving Average of $5.35Affimed (NASDAQ:AFMD) Share Price Passes Below Two Hundred Day Moving Average of $5.35August 24, 2024 | marketbeat.comShort Interest in Affimed (NASDAQ:AFMD) Decreases By 19.3%Affimed (NASDAQ:AFMD - Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 783,900 shares, a drop of 19.3% from the July 15th total of 971,500 shares. Based on an average daily trading volume, of 694,200 shares, the short-interest ratio is presently 1.1 days. Approximately 6.0% of the company's stock are short sold.August 16, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Receives Average Recommendation of "Buy" from AnalystsShares of Affimed (NASDAQ:AFMD - Get Free Report) have received an average recommendation of "Buy" from the four analysts that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages thAugust 14, 2024 | marketbeat.comAFMD Aug 2024 10.000 call (AFMD240816C00010000)August 13, 2024 | finance.yahoo.comKennedy Capital Management LLC Sells 622,134 Shares of Affimed (NASDAQ:AFMD)Kennedy Capital Management LLC cut its stake in Affimed (NASDAQ:AFMD - Free Report) by 98.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,106 shares of the biopharmaceutical company's stock after sellinAugust 2, 2024 | marketbeat.comAFMD Affimed N.V.August 1, 2024 | seekingalpha.comAffimed (AFMD) to Report Q2 Earnings: What's in the Cards?July 29, 2024 | msn.comBNP Paribas Financial Markets Sells 499,391 Shares of Affimed (NASDAQ:AFMD)BNP Paribas Financial Markets decreased its position in shares of Affimed (NASDAQ:AFMD - Free Report) by 87.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 72,584 shares of the biopharmaceutical company's stock after selling 499,391 shares during the quarJuly 24, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Given Consensus Recommendation of "Buy" by BrokeragesShares of Affimed (NASDAQ:AFMD - Get Free Report) have been given a consensus rating of "Buy" by the six research firms that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued raJuly 20, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Short Interest Up 8.5% in JuneAffimed (NASDAQ:AFMD - Get Free Report) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 1,000,000 shares, a growth of 8.5% from the June 15th total of 921,900 shares. Approximately 7.7% of the company's stock are short sold. Based on an average trading volume of 676,200 shares, the days-to-cover ratio is currently 1.5 days.July 16, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Given New $25.00 Price Target at LaidlawLaidlaw upped their price objective on Affimed from $15.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday.June 13, 2024 | marketbeat.comAFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024June 12, 2024 | investorplace.comAffimed Reports First Quarter 2024 Financial Results & Business UpdateJune 12, 2024 | globenewswire.com546,067 Shares in Affimed (NASDAQ:AFMD) Bought by Vestal Point Capital LPVestal Point Capital LP acquired a new position in Affimed (NASDAQ:AFMD - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 546,067 shares of the biopharmaceutical company's stocJune 9, 2024 | marketbeat.comAffimed (AFMD) Scheduled to Post Earnings on WednesdayAffimed (NASDAQ:AFMD) will be releasing earnings before the market opens on Wednesday, June 12, Zacks reports.June 6, 2024 | marketbeat.comAffimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024June 5, 2024 | globenewswire.comBNP Paribas Financial Markets Has $357,000 Stake in Affimed (NASDAQ:AFMD)BNP Paribas Financial Markets boosted its stake in shares of Affimed (NASDAQ:AFMD - Free Report) by 39.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 571,975 shares of the biopharmaceutical company's stock after buyingJune 5, 2024 | marketbeat.comAffimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortJune 1, 2024 | globenewswire.comShort Interest in Affimed (NASDAQ:AFMD) Grows By 13.0%Affimed (NASDAQ:AFMD - Get Free Report) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 230,700 shares, an increase of 13.0% from the April 30th total of 204,100 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily trading volume, of 93,400 shares, the short-interest ratio is currently 2.5 days.May 31, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Receives Average Rating of "Buy" from BrokeragesAffimed (NASDAQ:AFMD - Get Free Report) has received an average recommendation of "Buy" from the five brokerages that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that hMay 31, 2024 | marketbeat.comAffimed gets FDA fast track status for AFM24 for EGFR lung cancerMay 29, 2024 | msn.comAffimed's AFM24 With Atezolizumab For EGFR Wild-Type NSCLC Gets FDA Fast Track Status; Stock UpMay 29, 2024 | markets.businessinsider.comAffimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerMay 29, 2024 | globenewswire.comAffimed Announces Annual General Meeting of ShareholdersMay 28, 2024 | globenewswire.com7 Penny Biotech Stocks to Triple Your InvestmentMay 28, 2024 | investorplace.comAffimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024May 23, 2024 | globenewswire.comSmall-Cap Sensations: 3 Stocks Under $10 With 10X PotentialMay 17, 2024 | investorplace.comAffimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressMay 14, 2024 | globenewswire.comAffimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyApril 24, 2024 | finanznachrichten.deAffimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyApril 24, 2024 | globenewswire.comAffimed (NASDAQ:AFMD) Receives Average Recommendation of "Buy" from BrokeragesAffimed (NASDAQ:AFMD - Get Free Report) has been assigned an average rating of "Buy" from the five analysts that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issuApril 11, 2024 | marketbeat.comFY2024 EPS Estimates for Affimed (NASDAQ:AFMD) Lifted by Cantor FitzgeraldAffimed (NASDAQ:AFMD - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 earnings estimates for Affimed in a research report issued to clients and investors on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company wilApril 4, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Expected to Earn FY2028 Earnings of ($0.92) Per ShareAffimed (NASDAQ:AFMD - Free Report) - Stock analysts at HC Wainwright issued their FY2028 earnings estimates for Affimed in a research note issued to investors on Monday, April 1st. HC Wainwright analyst S. Ramakanth expects that the biopharmaceutical company will earn ($0.92) per share for the yApril 3, 2024 | marketbeat.comPromising Clinical Trials and Strategic Financial Management Affirm Buy Rating for AffimedApril 1, 2024 | markets.businessinsider.comAffimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call TranscriptApril 1, 2024 | finance.yahoo.com Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Ezekiel 7:23 (Ad)Jim Rickards here - former advisor to the CIA, the White House, and the Pentagon - with an urgent warning regarding the 2024 election. I don’t want to frighten you. But as an American patriot, it is my Christian duty to share the illegal election plot I’ve just uncovered. See, the Kamala campaign may be planning something so egregious… so despicable… and frankly, so unconstitutional that it could completely destroy our country. I predict a 50% market crash… Violent riots in the streets… And the potential introduction of martial law. It’s a scenario that only the Holy Bible could predict. AFMD Media Mentions By Week AFMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AFMD News Sentiment▼0.960.68▲Average Medical News Sentiment AFMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AFMD Articles This Week▼21▲AFMD Articles Average Week Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NKTX News Today CVKD News Today OGI News Today ZURA News Today SCLX News Today DMAC News Today MOLN News Today ETON News Today ATAI News Today ATOS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AFMD) was last updated on 10/10/2024 by MarketBeat.com Staff From Our PartnersBigger Than Nvidia?Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the n...InvestorPlace | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredAI Expert Reveals New PickWhy You Shouldn't Pour All Your Money Into Nvidia Jeff Brown, who predicted Nvidia's rise, warns against pu...Brownstone Research | SponsoredClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Pl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
